Characterization of KMT2A::MATR3 fusion in a patient with acute lymphoblastic leukemia and monitoring of minimal residual disease by nanoplate digital PCR

Pediatr Blood Cancer. 2023 Apr;70(4):e30120. doi: 10.1002/pbc.30120. Epub 2022 Dec 5.

Authors

Kazuyuki Komatsu^{1

2}, Kimiyoshi Sakaguchi¹, Daisuke Shimizu¹, Kaori Yamoto^{1

2}, Fumiko Kato^{1

2}, Isao Miyairi¹, Tsutomu Ogata^{1

2

3}, Hirotomo Saitsu²

Affiliations

¹ Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
² Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
³ Department of Pediatrics, Hamamatsu Medical Center, Hamamatsu, Japan.

PMID: 36468647
DOI: 10.1002/pbc.30120

No abstract available

Publication types

Letter

MeSH terms

Humans
Myeloid-Lymphoid Leukemia Protein* / genetics
Neoplasm, Residual
Nuclear Matrix-Associated Proteins
Oncogene Proteins, Fusion / genetics
Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
RNA-Binding Proteins

Substances

Myeloid-Lymphoid Leukemia Protein
Oncogene Proteins, Fusion
MATR3 protein, human
RNA-Binding Proteins
Nuclear Matrix-Associated Proteins